Single-dose and multiple-dose ascending study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of azp-3601, a synthetic parathyroid hormone analog, in healthy subjects and in subjects with hypoparathyroidism.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: AMOLYT PHARMA SAS
- Phase: I
- Execution start: 26/03/2021
- End of execution: 30/01/2022
- PI: JUAN DIEGO MEDIAVILLA GARCIA